5 unknown, 3 completed, 2 recruiting, 1 not yet recruiting. 11 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Unknown 5, Completed 3, Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Oxaliplatin: new trials by email Literature Review of Oxaliplatin trials Research Report on Oxaliplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab - Nanoliposomal Irinotecan, Cadonilimab | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2024-04-17 | 2024-12-24 |
| XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine - Tislelizumab, Bevacizumab | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 52 | 2023-07-07 | 2023-08-01 |
| Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors TACE, Tislelizumab, Lenvatinib - Hepatocellular Carcinoma, Lenvatinib | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 35 | 2023-07-01 | 2025-02-11 |
| Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer Tislelizumab - MSI-H Colorectal Cancer, Tislelizumab | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 25 | 2023-06-01 | 2023-05-09 |
| SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma sintilimab, Trastuzumab, S-1 plus oxaliplatin - HER2-positive, Locally Advanced Solid Tumor | Phase 2 | Unknown | Aiping Zhou | 44 | 2022-04-01 | 2022-04-06 |
| Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery Hepatic arterial infusion chemotherapy, Folfox Protocol, Donafenib - Carcinoma, Carcinoma, Hepatocellular | Phase 2 | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2021-12-27 | 2026-06-30 |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab - Hepatocellular Carcinoma, Bevacizumab | Phase 2 | Unknown | Sun Yat-sen University | 30 | 2021-01-01 | 2020-11-13 |
| FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma Irinotecan, 5-FU, Leucovorin - Stomach Neoplasms, Gastrointestinal Neoplasms | Phase 2 / Phase 3 | Unknown | Blokhin's Russian Cancer Research Center | 538 | 2019-01-29 | 2021-04-13 |
| Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer S-1 (TS-1) and Oxaliplatin (Oxalitin) - Elderly, S-1 | Phase 2 | Unknown | Soonchunhyang University Hospital | 36 | 2009-08-01 | 2009-08-18 |
| A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer Gemcitabine and Oxaliplatin - Advanced Biliary Tract Adenocarcinoma, Gemcitabine | Phase 2 | Completed | Soonchunhyang University Hospital | 40 | 2006-09-01 | 2014-05-20 |
| CCRT for Esophageal Cancer. Paclitaxel, Oxaliplatin, Radiotherapy - Esophageal Cancer, Concurrent Chemoradiotherapy | Phase 2 | Completed | Hangzhou Cancer Hospital | 34 | 2005-01-01 | 2016-02-17 |
Carcinoma, Hepatocellular (3) · Liver Neoplasms (2) · Stomach Neoplasms (2) · Carcinoma (1) · Colorectal Neoplasms (1) · Digestive System Neoplasms (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Recurrence (1)
Digestive System Diseases (7) · Neoplasms (7) · Neoplasms by Site (7) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (4) · Adenocarcinoma (3) · Gastrointestinal Neoplasms (3) · Liver Diseases (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Carcinoma (2) · Stomach Diseases (2) · Colonic Diseases (1) · Disease Attributes (1) · Esophageal Diseases (1)
Oxaliplatin (7) · Fluorouracil (2) · Leucovorin (2) · S 1 (combination) (2) · tislelizumab (2) · Bevacizumab (1) · Capecitabine (1) · Docetaxel (1) · Folfox protocol (1) · Gemcitabine (1) · Irinotecan (1) · Paclitaxel (1) · Radiotherapy (1) · Trastuzumab (1) · donafenib (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Soonchunhyang University Hospital (2) · Aiping Zhou (1) · Blokhin's Russian Cancer Research Center (1) · Hangzhou Cancer Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Zhengzhou University (1) · Zhejiang Cancer Hospital (1)
China (5) · Russia (1) · South Korea (1)
Dae Sik Hong, professor (1) · Fei Gao (1) · Ivan Stilidi, PhD (1) · Kangshun Zhu, Professor (1) · Lei Zhang, PHD (1) · Sang-Cheol Lee, M.D. (1)